Last reviewed · How we verify
Insulin Lispro Cartridge
At a glance
| Generic name | Insulin Lispro Cartridge |
|---|---|
| Also known as | Humalog |
| Sponsor | Inreda Diabetic B.V. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (NA)
- Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total Pancreatectomy (PHASE3)
- Portable Artificial Pancreas Applied for Youth and Adolescents (NA)
- Feasibility Trial Testing the Bionic Pancreas With ZP4207 (PHASE2)
- PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males (PHASE1)
- Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro (PHASE3)
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks (PHASE3)
- A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro Cartridge CI brief — competitive landscape report
- Insulin Lispro Cartridge updates RSS · CI watch RSS
- Inreda Diabetic B.V. portfolio CI